2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2159

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Abstract Number: 2160

Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Abstract Number: 2161

Comparison of Clinical Characteristics between African American and Caucasian Patients with Polymyositis and Dermatomyositis and Their Response to Conventional Treatment
Abstract Number: 2162

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathies
Abstract Number: 2163

Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice
Abstract Number: 2164

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
Abstract Number: 2165

Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Abstract Number: 2166

Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
Abstract Number: 2167

Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Abstract Number: 2168

Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis
Abstract Number: 2169

A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Abstract Number: 2170

Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
Abstract Number: 2171

Functional Measures and Patient Home Self-Assessments in the Idiopathic Inflammatory Myopathies
Abstract Number: 2172

Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
Abstract Number: 2173

Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].